One Global CMC Dossier? Digital Regulatory Submissions
Discover how digital CMC regulatory submissions, cloud collaboration, and AI accelerate the modernisation of manufacturing approvals and global pharma operations.
The pharmaceutical industry has modernised manufacturing at an extraordinary pace, yet regulatory submissions often remain fragmented across jurisdictions.
New evidence suggests that digital, cloud-based CMC regulatory submissions could dramatically reduce approval timelines for manufacturing changes, helping patients gain faster access to medicines while easing the burden on regulators and sponsors alike.
Why CMC Regulatory Submissions Need to Change
Chemistry, Manufacturing, and Controls (CMC) regulatory submissions are the regulatory foundation of every pharmaceutical product.
They indicate that manufacturing processes remain consistent, controlled, and capable of producing medicines that meet stringent quality standards throughout their lifecycle.
However, post-approval manufacturing changes remain some of the greatest operational challenges.
A single manufacturing improvement frequently requires multiple submissions to different national regulatory authorities, each following its own timelines, review practices, and information requests.
Although the underlying data are often identical, companies typically prepare multiple regional dossier versions, creating unnecessary duplication for both sponsors and regulators.
This fragmented approach slows implementation of manufacturing improvements, delays capacity expansion, and postpones patient access to medicines.
However, now recent research demonstrates that digital collaboration may offer a practical route towards a more harmonised future.
A New Model for Global CMC Collaboration
The recent study examined Amgen's international pilot for a post-approval manufacturing change involving Vectibix®, bringing together 27 participating national regulatory authorities through a shared cloud-based collaboration platform.
Rather than preparing numerous country-specific submissions, the company generated a single global dossier supported by structured content, automated authoring technologies, and digital information exchange.
The platform allowed participating regulators to review identical submission data simultaneously while sharing assessment reports, regulatory questions, and sponsor responses in real time.
The approach preserved each authority's independent decision-making while reducing repetitive reviews and duplicate information requests.
According to the pilot, the digital model delivered several operational improvements:
- One globally consistent CMC dossier instead of multiple regional versions
- Simultaneous submission across participating regulatory authorities
- Shared visibility of regulatory questions and responses
- Reduced manual document preparation and verification
- Faster communication between regulators and sponsors
Collectively, these capabilities illustrate how digitalisation can improve both regulatory efficiency and manufacturing agility without compromising regulatory review.
First Quarter 2026 State of Digital Health Funding
Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.
Faster Manufacturing Approvals Could Strengthen Pharma Supply Chains
Perhaps the most significant finding of the single CMC regulatory submission pilot was the impact on regulatory timelines.
Historically, comparable post-approval manufacturing changes often required more than three years to achieve broad international approval. During the pilot, however, 23 of the 27 participating regulatory authorities approved the variation within nine months, with several agencies requiring no additional information requests before granting approval.
Researchers also reported that cloud-based collaboration was approximately 75% more efficient than conventional document exchange, largely because participating authorities could view responses already provided to other regulators rather than requesting duplicate information.
For pharmaceutical manufacturers, these efficiencies extend beyond regulatory convenience and compliance.
Accelerating approval of manufacturing changes could support:
- Faster introduction of process improvements
- Increased manufacturing capacity
- Reduced medicinal waste
- More resilient global supply chains
- Earlier patient access to medicines
As biologics, advanced therapies, and increasingly complex manufacturing networks continue to expand, reducing unnecessary regulatory duplication may become an important competitive advantage.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Digital Quality Dossiers Represent the Next Stage of Manufacturing Innovation
The digital CMC regulatory submission pilot also reflects a broader transformation taking place across pharmaceutical technical operations.
Manufacturing digitalisation is no longer confined to smart factories, automation, or advanced analytics. Regulatory operations are beginning to undergo the same evolution.
Future submissions could be built using structured data standards rather than traditional document-centric dossiers.
Emerging technologies such as HL7 FHIR, structured content and data management (SCDM), cloud collaboration, and AI-assisted authoring could enable regulatory information to be created once and reused across multiple jurisdictions.
This would fundamentally change how CMC submissions are prepared.
Instead of assembling extensive regional documents, manufacturers could maintain continuously updated digital quality records capable of supporting multiple regulators simultaneously.
The concept aligns closely with wider international efforts towards regulatory reliance, greater harmonisation, and collaborative review models already being explored by organisations including the International Council for Harmonisation (ICH Q12), the World Health Organization (WHO), and the International Coalition of Medicines Regulatory Authorities (ICMRA).
Although policy, legal, and technological barriers remain, the pilot suggests that many of the required tools already exist.
How Pharmacy Innovation Is Changing Healthcare Delivery
Pharmacy is emerging as a critical but overlooked route to faster patient access. In this episode of Digital Pulse, Judit Mora explains how innovation, digital workflows, and pharmacy-led models can bypass traditional delays in healthcare delivery.
Manufacturing Modernisation Must Include Regulatory Modernisation
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Pharmaceutical manufacturing has entered an era of unprecedented technological innovation. Continuous manufacturing, digital twins, artificial intelligence, and advanced analytics are reshaping production environments across the industry.
Yet manufacturing innovation cannot achieve its full potential if regulatory processes continue to rely on fragmented, document-heavy submission models.
The Vectibix pilot demonstrates that digital CMC regulatory submissions can improve transparency, reduce duplication, accelerate regulatory decisions, and strengthen collaboration between sponsors and health authorities.
Rather than replacing regulatory oversight, cloud-based collaboration enhances access to information while preserving independent scientific assessment.
This means that the next generation of manufacturing excellence will depend not only on smarter production technologies, but also on smarter regulatory ecosystems capable of supporting increasingly global pharmaceutical supply chains.
At Pharmatica, we explore how digital manufacturing, regulatory innovation, and technical operations are transforming pharmaceutical production. By analysing emerging technologies alongside evolving regulatory frameworks, we help life sciences leaders understand how operational excellence translates into faster innovation, greater resilience, and improved patient access.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What are CMC regulatory submissions?
CMC regulatory submissions are documents submitted to health authorities that describe a medicine's chemistry, manufacturing processes, quality controls, and product consistency. They demonstrate that pharmaceutical products can be manufactured safely and reliably throughout their lifecycle.
Why are post-approval manufacturing changes difficult to implement?
Manufacturing changes often require separate submissions to multiple regulatory authorities, each with different review processes and timelines. This duplication can delay approvals, increase administrative work, and slow the implementation of manufacturing improvements.
How can digital CMC regulatory submissions improve pharmaceutical manufacturing?
Digital CMC regulatory submissions use structured data, cloud-based collaboration, and automated authoring technologies to reduce duplicate documentation, improve communication between regulators and sponsors, and accelerate review timelines while maintaining regulatory oversight.
What is regulatory reliance in pharmaceutical manufacturing?
Regulatory reliance is an approach in which one regulatory authority considers the scientific assessments or decisions of another trusted authority when reviewing a submission. This can reduce duplication while allowing each regulator to make an independent decision for its own jurisdiction.
How will AI influence future CMC regulatory submissions?
AI is expected to support automated dossier authoring, structured content management, data validation, and quality checks. Combined with cloud collaboration and international data standards, AI could help create faster, more consistent, and globally harmonised regulatory submissions.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)